BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Boehringer Ingelheim and OSE Immunotherapeutics SA, a clinical-stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.

June 28, 2024

Vol.50 No.26

Obituary

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

YOU MAY BE INTERESTED IN

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Exscientia builds AWS AI-powered platform to advance drug discovery

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

“Father of tamoxifen” V. Craig Jordan dies at 76

Renew today!

Subscriber content

Login

BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

YOU MAY BE INTERESTED IN

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Exscientia builds AWS AI-powered platform to advance drug discovery

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

“Father of tamoxifen” V. Craig Jordan dies at 76

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC